Your browser doesn't support javascript.
loading
Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption.
Gegenschatz-Schmid, Katharina; Buzzi, Stefano; Grossmann, Jonas; Roschitzki, Bernd; Urbanet, Riccardo; Heuberger, Roman; Glück, Dorothea; Zucker, Arik; Ehrbar, Martin.
Afiliação
  • Gegenschatz-Schmid K; Department of Obstetrics, University and University Hospital of Zurich, Laboratory for Cell and Tissue Engineering, Schmelzbergstrasse 12, PATHG 48, Zurich 8091, Switzerland.
  • Buzzi S; Qvanteq AG, Zurich, Switzerland.
  • Grossmann J; Functional Genomics Center Zurich, University of Zurich/ETH Zurich, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Roschitzki B; Functional Genomics Center Zurich, University of Zurich/ETH Zurich, Switzerland.
  • Urbanet R; Department of Obstetrics, University and University Hospital of Zurich, Laboratory for Cell and Tissue Engineering, Schmelzbergstrasse 12, PATHG 48, Zurich 8091, Switzerland.
  • Heuberger R; RMS Foundation, Bettlach, Switzerland.
  • Glück D; Blood Transfusion Service SRC, Zurich, Switzerland.
  • Zucker A; Qvanteq AG, Zurich, Switzerland.
  • Ehrbar M; Department of Obstetrics, University and University Hospital of Zurich, Laboratory for Cell and Tissue Engineering, Schmelzbergstrasse 12, PATHG 48, Zurich 8091, Switzerland. Electronic address: martin.ehrbar@usz.ch.
Acta Biomater ; 137: 331-345, 2022 01 01.
Article em En | MEDLINE | ID: mdl-34673227
ABSTRACT
Blood-contacting medical implants made of Nitinol and other titanium alloys, such as neurovascular flow diverters and peripheral stents, have the disadvantage of being highly thrombogenic. This makes the use of systemic (dual) anti-platelet/anticoagulant therapies inevitable with related risks of device thrombosis, bleeding and other complications. Meeting the urgent clinical demand for a less thrombogenic Nitinol surface, we describe here a simple treatment of standard, commercially available Nitinol that renders its surface ultra-hydrophilic and functionalized with phosphate ions. The efficacy of this treatment was assessed by comparing standard and surface-treated Nitinol disks and braids, equivalent to flow diverters. Static and dynamic (Chandler loop) blood incubation tests showed a drastic reduction of thrombus formation on treated devices. Surface chemistry and proteomic analysis indicated a key role of phosphate and calcium ions in steering blood protein adsorption and avoiding coagulation cascade activation and platelet adhesion. A good endothelialization of the surface confirmed the biocompatibility of the treated surface. STATEMENT OF

SIGNIFICANCE:

Titanium alloys such as Nitinol are biocompatible and show favorable mechanical properties, which led to their widespread use in medical implants. However, in contact with blood their surface triggers the activation of the intrinsic coagulation cascade, which may result in catastrophic thrombotic events. The presented results showed that a phosphate functionalization of the titanium oxide surface suppresses the activation of both coagulation cascade and platelets, avoiding the subsequent formation of a blood clot. This novel approach has therefore a great potential for mitigating the risks associated to either thrombosis or bleeding complications (due to systemic anticoagulation) in patients with cardiovascular implants.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Ligas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteômica / Ligas Idioma: En Ano de publicação: 2022 Tipo de documento: Article